Showing 8131-8140 of 10143 results for "".
- Dove Gives Back With the Dove Nature Regeneration Projecthttps://practicaldermatology.com/news/dove-gives-back-with-the-dove-nature-regeneration-project/2461947/Dove is introducing their Nature Regeneration Project, a new initiative to protect nature and tackle climate change. In partnership with the Rimba Collective, Dove will help protect and restore 123,000 acres of rainforest in Southeast Asia –an area 8x the size of&n
- Arctiva’s Eczema Cream Scores NEA Seal of Acceptancehttps://practicaldermatology.com/news/arctivas-eczema-cream-scores-nea-seal-of-acceptance/2461946/
- Found: 135 New Melanin Genes Responsible for Pigmentationhttps://practicaldermatology.com/news/found-135-new-melanin-genes-responsible-for-pigmentation/2461927/Researchers have discovered 135 new genes associated with pigmentation. “To understand what actually causes different amounts of melanin to be produced, we used a technology called CRISPR-Cas9 to genetically engineer cells,” explains study author
- PSA: Vets Warn That Minoxidil May Be Deadly to Petshttps://practicaldermatology.com/news/vets-warn-that-minoxidil-may-be-deadly-to-pets/2461917/Products like Rogaine, which contain minoxidil, can be very dangerous to animals, warn toxicology experts at Pet Poison Helpline. “Cats are particularly sensitive to this medication, and any exposure can result in severe poisoning and potentially death,” says Renee
- NPF Welcomes Four New Board Membershttps://practicaldermatology.com/news/npf-welcomes-four-new-board-members/2461907/The National Psoriasis Foundation (NPF) is adding four new members to the NPF Board of Directors. Andrew Blauvelt, MD, MBA, Valerie Harrison, PhD, Brian Janssen, and Diana Sandler, MD. will serve two-year terms effective July 1, 2023. Dr. Blauvelt will also serve as the Chair
- Another FDA Nod for SkinStylus Microneedling Device: Facial Acne Scarshttps://practicaldermatology.com/news/another-fda-nod-for-skinstylus-microneedling-device-facial-acne-scars/2461904/
- Lupus Foundation of America Awards Five Summer Fellowship Grantshttps://practicaldermatology.com/news/lupus-foundation-of-america-awards-five-summer-fellowship-grants/2461899/The Lupus Foundation of America announced five recipients of the
- Research Closes in on the Genetic Factors Underlying HS Riskhttps://practicaldermatology.com/news/research-closes-in-on-the-genetic-factors-underlying-hs-risk/2461893/Researchers have identified genetic locations for increased risk of hidradenitis suppurativa (HS). “This discovery is highly relevant because these changes may effect nearby genes in a way that leads to improper development of hair follicles and predispose them to the rupture,&rdq
- DFD-29 Bests Competition for Papulopustular Rosacea in Adultshttps://practicaldermatology.com/news/dfd-29-bests-competition-for-papulopustular-rosacea-in-adults/2461858/Minocycline Hydrochloride Modified Release Capsules (DFD-29) outperformed Oracea (doxycycline) capsules and placebo for the treatment of moderate-to-severe papulopustular rosacea in adults, according to positive topline results from two Phase 3 studies. Journey Medical&rs
- WCD News: Connect Biopharma's Rademikibart Earns High Marks in ADhttps://practicaldermatology.com/news/wcd-news-connect-biopharmas-rademikibart-earns-high-marks-in-ad/2461851/Four new studies support the efficacy and safety of rademikibart in atopic dermatitis (AD), Connect Biopharma reports. Rademikibart (CBP-201), a next-generation IL-4Rα antibody, achieved all primary and secondary endpoints in a randomized pivotal trial for moderate-to-severe